MOG and in situ carcinoma: Finally, the anti-MOG B cell frequency was decreased neither in a small group of MS patients with secondary progressive form (SPMS) nor in the CIS patients suggesting that this alteration occurs in the course of the relapse-remitting disease rather than at its onset.